SCHEDULE: Hillhouse Investment Discloses 9.5% Stake in ArriVent BioPharma

Hillhouse Investment Management, Ltd. has reported a 9.5% beneficial ownership stake in ArriVent BioPharma, Inc., holding 3,929,117 shares of common stock.

Summary

• Hillhouse Investment Management, Ltd. (HIM), an exempted Cayman Islands company, filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in ArriVent BioPharma, Inc.
• HIM beneficially owns 3,929,117 shares of ArriVent BioPharma, Inc.'s common stock, par value $0.0001 per share.
• This ownership stake represents 9.5% of the total class of securities outstanding.
• The percentage is calculated based on 41,281,361 shares of common stock outstanding as of November 7, 2025, as reported in the Company's Form 10-Q filed on November 10, 2025.
• HIM acts as the sole management company for Hillhouse Venture Fund V, L.P., Hillhouse Healthcare Fund, L.P., and Hillhouse Venture Fund VI, L.P.
• The shares are held by VSUM VI Holdings Limited (wholly owned by Venture Fund V), VSUM VIII Holdings Limited (wholly owned by Healthcare Fund), and ARVT Holdings Limited (wholly owned by Venture Fund VI).
• HIM is deemed to be the beneficial owner and controls the sole voting and sole dispositive power over these 3,929,117 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive, as a significant stake by a reputable investment firm like Hillhouse can be interpreted as a vote of confidence in ArriVent BioPharma's prospects, though it's a passive disclosure.

Positives

• A significant stake of 9.5% by a prominent investment firm like Hillhouse Investment Management, Ltd. can signal confidence in ArriVent BioPharma, Inc.'s future prospects.
• Hillhouse Investment Management, Ltd. is classified as an Investment Adviser (IA), indicating a professional and strategic investment approach.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant investments by established firms like Hillhouse Investment Management, known for its focus on healthcare and technology, often indicate a positive long-term view on the target company's sector and specific business model. This could suggest confidence in ArriVent BioPharma's position within the biopharmaceutical industry.

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may increase investor confidence and potentially influence stock valuation positively.
• ArriVent BioPharma, Inc.: The company gains a significant institutional shareholder, which could provide stability and potential strategic support.

Next Steps

• NA

Key Dates

Recommendation

While the disclosure of a significant stake by Hillhouse Investment Management is a positive signal, a Schedule 13G filing is a passive ownership report and does not provide sufficient operational or financial details to warrant a 'buy' recommendation. It suggests institutional confidence, but further fundamental analysis of ArriVent BioPharma's business is required for a stronger recommendation. Therefore, a 'hold' is appropriate, acknowledging the positive signal without overcommitting based solely on this disclosure.

Keywords

ArriVent BioPharma, Hillhouse Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Biopharma Investment, Institutional Investor, Equity Stake